Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a research note published on Monday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Several other analysts also recently weighed in on RVNC. Needham & Company LLC reissued a “hold” rating on shares of Revance Therapeutics in a research note on Friday, November 8th. Barclays lowered their target price on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a research note on Monday, December 23rd. Mizuho reduced their price target on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a research report on Tuesday, December 10th. Finally, HC Wainwright reaffirmed a “neutral” rating and issued a $6.60 price target on shares of Revance Therapeutics in a research note on Friday, November 8th. Nine research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $8.39.

Revance Therapeutics Trading Up 1.2 %

Shares of NASDAQ RVNC opened at $3.29 on Monday. The stock’s 50-day moving average is $3.61 and its 200 day moving average is $4.54. The stock has a market cap of $343.44 million, a price-to-earnings ratio of -1.70 and a beta of 0.86. Revance Therapeutics has a 1-year low of $2.30 and a 1-year high of $7.56.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The business had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $67.73 million. On average, analysts forecast that Revance Therapeutics will post -1.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Vanguard Personalized Indexing Management LLC purchased a new position in Revance Therapeutics in the second quarter worth about $33,000. Hsbc Holdings PLC bought a new stake in shares of Revance Therapeutics during the second quarter valued at approximately $38,000. FORA Capital LLC purchased a new position in Revance Therapeutics in the 3rd quarter worth approximately $54,000. Creative Planning bought a new position in Revance Therapeutics in the 3rd quarter valued at approximately $56,000. Finally, Sei Investments Co. boosted its stake in Revance Therapeutics by 52.5% during the 2nd quarter. Sei Investments Co. now owns 22,167 shares of the biopharmaceutical company’s stock valued at $57,000 after purchasing an additional 7,628 shares during the last quarter. Institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.